Market Overview

Afternoon Market Gainers

Related BLUE
BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts
Adam Feuerstein On Biotechs: 'I Have An Itchy Trigger Finger On Hypocrisy'
Related NKTR
Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade
Nektar Reports Preclinical Data Presented at AACR, Showed Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition

Bluebird Bio (NASDAQ: BLUE) traded up 49.55 percent to $25.41. Wednesday's IPO for the company was initially priced at $17.

Nektar Therapeutics (NASDAQ: NKTR) rose 9.99 percent to $10.79 after announcing positive top-line results from a human abuse liability (HAL) study for NKTR-181.

Gevo (NASDAQ: GEVO) climbed 9.23 percent to $2.26 after yesterday's announcement that it had resumed commercial production of Isobutanol.

Keryx BioPharma (NASDAQ: KERX) shot up 6.50 percent to $8.16 after analysts at JP Morgan initiated coverage on the stock with an Overweight rating.

MannKind (NASDAQ: MNKD) regained 6.48 percent to $7.03 after yesterday's double-digit drop.

Posted-In: News Movers


Related Articles (GEVO + BLUE)

View Comments and Join the Discussion!